Given the essential roles of mutant BRAF in melanoma initiation, drugs targeting BRAF mutation were developed and bring great benefits to patients with unresectable and metastatic melanoma, such as Vemurafenib [6, 7]. This evidence concerns the gene BRAF and metastatic melanoma.